Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Instil Bio ( (TIL) ) has shared an announcement.
Instil Bio, Inc., through its subsidiary Complex Therapeutics LLC, has secured an $85.6 million term loan from Midland National Life Insurance Company to refinance loans associated with its Tarzana, California facility. The loan agreement includes a two-year term with a one-year extension option, interest-only payments, and various conditions and covenants, reflecting a strategic move to streamline financial obligations and reinforce property security, which could impact its overall financial stability and operational focus.
More about Instil Bio
Instil Bio, Inc. operates in the biotechnology industry, focusing on the development of innovative therapies. It is involved in the construction and development of facilities, such as the one in Tarzana, California, through its subsidiary, Complex Therapeutics LLC.
YTD Price Performance: 170.47%
Average Trading Volume: 141,928
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $134.5M
Learn more about TIL stock on TipRanks’ Stock Analysis page.
